EGFR and non-small cell lung carcinoma: More recently, FLAURA-2, an international phase III study, demonstrated the increased efficacy of osimertinib in combination with pemetrexed and platinum-based chemotherapy in advanced NSCLC patients harboring an EGFR E19del or L858R mutation.